Cancer researchers in New York are exploring the concept of using step counts for cancer prognosis. If further studies back it up, the technique might help predict outcomes for people with mesothelioma. The new study involved people with non-small cell lung cancer. The patients wore commercial fitness trackers so doctors could see how much they walked. The researchers compared step levels with treatment outcomes. They concluded that there is value to using step counts for cancer prognosis. It may even be more effective than some more traditional methods for predicting survival. Cancer Prognosis and Chemoradiotherapy Mesothelioma survival usually depends on how well patients respond to standard treatments. Healthier, more active cancer patients tend to have better outcomes. Chemotherapy and radiation … Continue reading Step Counts for Cancer Prognosis: Could it Work for Mesothelioma?
There is new evidence supporting the use of low-dose aspirin for cancer survival. The evidence comes from two new retrospective studies. The first involved patients with head and neck cancer. The second focused on patients with early-stage non-small cell lung cancer (NSCLC). NSCLC is similar to mesothelioma in many ways. Mesothelioma is an aggressive cancer that is often fatal within a year of diagnosis. Based on the new findings, some mesothelioma patients may consider talking to their doctors about aspirin for cancer survival Anti-Inflammatories and Cancer Treatment Anti-inflammatory drugs like aspirin can cut the risk for heart disease and heart attack. But research led by the Roswell Park Cancer Center shows they may have similar benefits for people with cancers … Continue reading Should Mesothelioma Patients Take Aspirin for Cancer Survival?
A UK study suggests that successful talc pleurodesis for mesothelioma improves survival better than other lung fluid treatments. Researchers in Oxford’s Chest Diseases Department analyzed the outcomes of two groups of pleural mesothelioma patients. Both groups underwent talc pleurodesis for mesothelioma. The patients whose lung fluid did not come back after treatment experienced longer survival. Mesothelioma patients who had to be retreated did not live as long. Pleural Effusion in Mesothelioma The pleura is a membrane that surrounds and encases the lungs. It is supposed to be flexible and allow the lungs to move when a person breathes. But patients with pleural mesothelioma often develop pleural effusion. Pleural effusion is a build-up of excess fluid in the space between the … Continue reading Talc Pleurodesis for Mesothelioma May Extend Survival
A new article suggests that non-invasive TTFields treatment for mesothelioma has the potential to save lives – as long as enough physicians accept it. TTFields stands for Tumor Treating Fields. It is an electricity-based treatment approved by the FDA for use along with standard mesothelioma chemotherapy. Cancer researchers from West Cancer Center and Research Institute wrote the new article for The Oncologist. They say the success of TTFields treatment for mesothelioma depends on doctors learning the logistics of using it. How Does TTFields Treatment for Mesothelioma Work? TTFields use low-intensity alternating electric fields. When these electric fields hit a mesothelioma tumor, they disrupt normal cell division. If cancer cells cannot divide properly, they are less likely to spread out of … Continue reading TTFields Treatment for Mesothelioma: Physician Acceptance is Critical
Japanese researchers are reminding doctors to watch for signs of peritoneal mesothelioma in people who have undergone past radiotherapy. Many cancer patients undergo radiotherapy. Radiation disrupts the DNA inside cancer cells. This can help keep these malignant cells from replicating and spreading. But radiation treatment also has a downside. It can cause cellular changes in healthy cells, too. This can cause side effects right away, or decades later. As more people have radiation and survive, scientists at the Shinshu University School of Medicine say more of them could develop radiation-related mesothelioma later in life. But the signs of peritoneal mesothelioma years after radiation are easy to miss. Peritoneal Mesothelioma Case Study The new report is based on the case of … Continue reading Signs of Peritoneal Mesothelioma After Radiotherapy
An Indian woman in still alive two years after a mesothelioma diagnosis thanks to a remarkable mesothelioma tumor response to nivolumab. Nivolumab is sold under the brand name Opdivo. It is a type of immunotherapy. Nivolumab is sometimes used for lung cancer that progresses after chemotherapy. A hospital in Mumbai tried nivolumab on a pleural mesothelioma patient after several types of chemotherapy did not work. Doctors say the mesothelioma tumor response to nivolumab was so great that the patient no longer needed supplemental oxygen. Opdivo in Mesothelioma Treatment Opdivo is not FDA-approved for mesothelioma treatment. Only Alimta (pemetrexed) holds that designation. But pleural mesothelioma grows quickly and is hard to treat. Even the gold standard therapies often do not work … Continue reading Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study
A new report suggests that CRS/HIPEC treatment has helped to double the odds of surviving peritoneal mesothelioma in Sweden. Researchers collected data from the Swedish National Cancer Registry. A total of 102 peritoneal mesothelioma cases were included from two separate 5-year time periods. The report shows that, since CRS/HIPEC treatment was introduced in Sweden, overall survival of peritoneal mesothelioma increased from 7 to 15 months. At 5 years, twice as many peritoneal mesothelioma patients were still alive. The researchers conclude that this is likely due, at least in part, to CRS/HIPEC treatment. Surviving Peritoneal Mesothelioma Peritoneal mesothelioma is an aggressive cancer that starts on the membrane lining the abdomen. It is almost always caused by accidental swallowing of microscopic asbestos … Continue reading CRS/HIPEC Treatment Helps Double Survival Among Swedish Mesothelioma Patients
There is new evidence that adding a drug called vorinostat to immunotherapy might help relapsed pleural mesothelioma patients. The new study comes from the Moffitt Cancer Center in Tampa. It focused on patients with non-small cell lung cancer. Non-small cell lung cancer is similar to pleural mesothelioma in many ways. The study found that patients who received vorinostat along with an immune checkpoint inhibitor had better results. The findings could be good news for relapsed pleural mesothelioma patients, too. Different Immunotherapy Drugs Vorinostat is sold under the brand name Zolinza. It is a histone deacetylase (HDAC) inhibitor. HDAC inhibitors alter the way proteins are expressed inside cells. They also stimulate the immune system. Immune checkpoint inhibitors (ICIs) like Keytruda also … Continue reading New Hope for Relapsed Pleural Mesothelioma?
Belgian scientists say they are still not sure about the effect of chemotherapy on immunotherapy for mesothelioma. They reached that conclusion after testing several different chemotherapy drugs on mesothelioma cells in the lab. The combination of chemotherapy and immunotherapy is “chemoimmunotherapy”. It aims to harness the unique powers of each treatment approach. A meta-analysis last May called chemoimmunotherapy the “next frontier” in mesothelioma treatment. But the new Belgian study on the effect of chemotherapy on immunotherapy highlights how much doctors still do not know about the combo. Immune Checkpoints Are the Key When it is working properly, the immune system is supposed to find and kill cancer cells before they become mesothelioma tumors. But mesothelioma cells can hide from the … Continue reading Effect of Chemotherapy on Immunotherapy for Mesothelioma
MD Anderson researchers say too many patients who might benefit from IMRT for mesothelioma never complete the treatment. The problem could be impacting their survival. Intensity Modulated Radiotherapy (IMRT) is a type of targeted radiation. It is designed to direct as much radiation as possible into the mesothelioma tumor without harming the surrounding tissue. Patients who have a combination of surgery, chemotherapy, and IMRT for mesothelioma have the best odds of survival. But at MD Anderson Cancer Center, only two thirds of eligible patients completed IMRT after mesothelioma surgery. The new study aimed to find out why. Trimodal Therapy and Mesothelioma Survival Malignant mesothelioma rarely responds to a single cancer therapy. Trimodal therapy combines several different treatments to maximize success. … Continue reading IMRT for Mesothelioma: Barriers to Completing Treatment